ProfessionalNo New Dates

Psilocybin Assisted Therapy for Existential Distress in Cancer Patients by Jeff Guss, MD

This course covers psilocybin-assisted therapy for existential distress in cancer patients, including the study rationale, participant selection, preparation, dosing-session support, and integration. It also discusses the historical and cultural context of psychedelics and the role of the therapist in supporting inner-

Provider

IPI

English

Schedule

000 years

Enrollment

Price on request

Course Overview

This course examines psilocybin-assisted therapy for existential distress in cancer patients. It explains how the study was shaped by the concept of existential distress, including how participants were selected, how preparation was structured, and how integration was approached after the dosing session. The content also reviews the broader history of psychedelics in culture, including their long-standing use in indigenous and religious contexts. It presents existential distress as a response to cancer diagnosis marked by fear, sadness, loss of meaning, and questioning of life’s purpose. The course describes the therapist’s role as supportive and minimally directive during the session, with emphasis on helping participants remain with their inner experience. It also addresses post-session integration and the relevance of transpersonal psychology in spiritual and existential work.

Who is this for?

Clinicians, therapists, and mental health professionals interested in psychedelic-assisted therapy, cancer-related existential distress, and integration work.

About the Provider

Educational platform co-founded by Dr. Will Van Derveer and Keith Kurlander that trains therapists, physicians, and nurses in psychedelic-assisted therapy through a year-long online program taught by 50+ experts including Robin Carhart-Harris, Michael Pollan, and Rick Doblin. IPI's curriculum covers evidence-based protocols for PTSD, depression, and anxiety, and partners with the Usona Institute and MAPS to prepare clinicians for emerging MDMA- and psilocybin-assisted treatments.

Related Courses

View all courses